Chris Ryan

The complete response rate was 88%.

Alexey Danilov, MD, PhD, discussed the importance of reassessing sequencing stratagems in the face of a growing toolbox of targeted therapies in DLBCL.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial.

The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.

Zever-cel is being assessed in the phase 2 LUMMICAR-2 trial (NCT03915184) in North America, previously reporting results of an ORR of 100% among 11 patients.

The new PDUFA date of lifileucel is set for Februrary 24, 2024.

Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.

Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.

The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Participants in the trial achieved a sustained response and experienced low-grade toxicity.

CT-0508 was granted a fast track designation in September 2021 for use as a potential therapy for patients with solid tumors.

CT103A is co-developed by IASO Biotherapeutics and Innovent Biologics.

Patients in the liso-cel arm had more favorable overall least square mean changes from baseline to day 126 vs the SOC arm in quality of life scores.

Patients treated with cilta-cel had a 76% reduction in the risk of death compared to patients treated with physician's choice of treatment.